Navigation Links
ESTEVE Announces the Publication of Comprehensive Phase I Data for a Novel Oral, First-in-class New Chemical Entity (NCE),E-52862, a Sigma-1 Receptor Antagonist (S1RA) Being Developed for Pain
Date:9/4/2012

(telemetry, triplicate 12-lead ECGs, 24-hour Holter ECGs). Pharmacokinetic assessments were performed in each study and results demonstrate a favourable pharmacokinetic and pharmacodynamic profile, supporting oral, once-daily administration of E-52862.

The E-52862 Phase I programme is now complete and included over 300 human subjects (more than 250 received E-52862).  Results from the overall programme show favourable safety, tolerability, pharmacodynamic and pharmacokinetic profiles at all doses of E-52862 tested.

Today, the E-52862 clinical programme focuses on pain management - highlighting both neuropathic pain and the potentiation of opioid analgesia. The Phase II clinical trial programme for E-52862 began early in 2012.  The clinical project leader for E-52862, Roser Vives, M.D. commented that "Because of the MOA and data available to date, we are evaluating E-52862 in four different types of neuropathic pain and for treatment of pain in patients receiving opioids (for the enhancement of the analgesic effect and better tolerability). E-52862 also has potential applications for other neurological and psychiatric indications".

E-52862, whose MOA is both novel and complementary to that of other analgesic compounds, could provide a much-needed addition to future pain management choices with, perhaps, the option to be used as monotherapy, as well as in combination with other pain relief compounds, depending on the type of patient and clinical indication.

About ESTEVE

ESTEVE is a leading pharmaceutical chemical group based on Barcelona (Spain) with significant international presence.  Since it was founded in 1929, ESTEVE has been firmly committed to excellence in healthcare, dedicating efforts to innovative R&D of new medicines for unmet medical needs and focusing on high science and evidence-based research. ESTEVE has a strong partnership approach to drug discovery, development and commercialisation. The company
'/>"/>

SOURCE ESTEVE
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ESTEVE Communicates its R&D Through a New Interactive Platform
2. Texas Medical Center, the largest concentration of medical research, educational and healthcare organizations in the world, announces the first Houston Stem Cell Summit to highlight the latest stem cell research and commercialization efforts
3. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
4. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
5. Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Companys Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury
6. Clinical Site Services, Industry Leader in Patient Enrollment Solutions, Announces New Website
7. Debiopharm Announces First Patient Enrolled in Phase III Study for the Rare Disease Central Precocious Puberty
8. Pinnaclife, Inc., Announces NDC, Inc., to Exclusively Distribute the New Animal Health Product Line!
9. Elsevier / Gold Standard Announces New Drug Class Overviews for Clinical Pharmacology
10. Inspiration Biopharmaceuticals Announces New Global Commercialization Agreements with Ipsen
11. UBM Announces Partnership Agreement With Trade Organisation - SIPPO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 2014 EvoDerma ’s NOOME Anti-Aging Motion ... device now comes with a second treatment cup to help ... The new cup is thinner on the edges for a ... rough, thin and uneven surfaces on the face, neck and ... stimulating treatment on areas such as the cheeks and neck, ...
(Date:7/10/2014)... DALLAS , July 10, 2014  Kainos Capital, ... consumer brands, today announced that it has acquired the ... stake in the business. Terms of the transaction were ... loss and meal replacement business that markets ready-to-drink shakes, ... North America and in the ...
(Date:7/10/2014)... -- According to the International Atomic Energy Agency ... from terrorists acquiring sufficient quantities of plutonium or ... nuclear explosive device. The IAEA also notes that ... gram-level quantities, which can be challenging to detect ... new study appearing this week in the ...
(Date:7/10/2014)... disorders has been extremely challenging because there are many ... to cause disease. Now investigators reporting in the July ... Stem Cell describe a strategy that may help ... risk factors or environmental exposures to affect the development ... variant that may predispose individuals to schizophrenia. , ...
Breaking Biology Technology:Introducing a New Bonus Treatment Cup for EvoDerma’s NOOME Anti-Aging Motion 2Kainos Capital Acquires Slim-Fast From Unilever 2Sensitive detection method may help impede illicit nuclear trafficking 2New strategy could uncover genes at the root of psychiatric illnesses 2
... annotated serum, tissue and blood samples are ... available for Genomic and Proteomic Research, ... that develops products and services to help accelerate,advancements in ... management company dedicated to innovation in human tissue,research, have ...
... Novo Nordisk, a,healthcare company with an 84-year history ... the appointment of Alan C. Moses, M.D. as,vice ... the,chief medical officer of Novo Nordisk Inc., the ... talent to integrate the science of discovery with,new ...
... 9 ExonHit Therapeutics, a drug,and diagnostic discovery ... to its strategic partnership with bioMerieux in the ... amendment, ExonHit will gain,commercial rights on the diagnostic ... a greater flexibility to initiate new research and,development ...
Cached Biology Technology:Oncology Metrics and Cureline Announce Joint Marketing Agreement 2Oncology Metrics and Cureline Announce Joint Marketing Agreement 3Novo Nordisk Appoints Alan C. Moses as Chief Medical Officer Worldwide 2ExonHit and bioMerieux Amend Their Strategic Partnership 2ExonHit and bioMerieux Amend Their Strategic Partnership 3
(Date:7/11/2014)... Janeiro, Brazil- In the brains of all vertebrates, ... allows an electric or chemical signal to be ... synapses, which are the most abundant type of ... formation is crucial for learning, memory, perception and ... synapses critical for brain function. For instance, ...
(Date:7/10/2014)... July 1, 2014 Smart technology emphasis ... convenience and improved security: NXT-ID, Inc. (OTCBB: NXTD), eBay Inc. ... GOOG ), Apple Inc. (NASDAQ: AAPL ), Visa ... MA) NXT-ID, Inc., (OTCQB: NXTD) a biometric authentication company ... that the second series of 30 second spots on CNBC ...
(Date:7/10/2014)... 2014 Research and Markets ( http://www.researchandmarkets.com/research/h7h8lq/gesture ... "Global Gesture Recognition & Touch-Less Sensing (2D, 3D, ... report to their offering ... & Touch-Less Sensing Market to Grow Exponentially. Touch-less ... but the companies were unable to leverage this ...
Breaking Biology News(10 mins):Blame it on the astrocytes 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 2Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 3Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 4Advantages for Digital Wallets Eliminate Need to Carry Credit Cards - Large Scale CNBC Ad Campaign for Latest Smart Wallet to Commence July 7th 5Global Gesture Recognition & Touch-Less Sensing (2D, 3D, Ultrasonic, IR, Capacitive) Market - Forecasts to 2020 2
... New Geosphere articles include additions to several special ... Sea-level Change Offshore New Jersey"; "The ANDRILL McMurdo Ice Shelf ... Deep Sea and Beyond: Contributions to Marine Geology in Honor ... of the Colorado River System II." Topics include, ...
... in collaboration with the Environmental Services Unit at the Alejandro ... of Caribbean orchid. The Caribbean islands have been ... over two centuries now. Suffice to say that the studies ... archipelagos contributed to the emergence of the theory of evolution. ...
... , NEW YORK (December 26, 2012)The Wildlife Conservation ... three key landscapes across the big cat,s range due ... strong government partnerships. The successes are much-needed good ... all-time lows due to the combined threat of poaching, ...
Cached Biology News:Geosphere covers Grand Canyon, deep drill coring, Death Valley, and more 2Geosphere covers Grand Canyon, deep drill coring, Death Valley, and more 3Geosphere covers Grand Canyon, deep drill coring, Death Valley, and more 4Geosphere covers Grand Canyon, deep drill coring, Death Valley, and more 5Geosphere covers Grand Canyon, deep drill coring, Death Valley, and more 6Geosphere covers Grand Canyon, deep drill coring, Death Valley, and more 7Geosphere covers Grand Canyon, deep drill coring, Death Valley, and more 82 new species of orchid found in Cuba 22 new species of orchid found in Cuba 3Tigers roar back: Good news for big cats in 3 key landscapes 2Tigers roar back: Good news for big cats in 3 key landscapes 3
Goat polyclonal to HNF4 ( Abpromise for all tested applications). Antigen: Synthetic peptide: RLSKTLVDMDMADY (Human) N terminal. Entrez GeneID: 3172 Swiss Protein ID: P41235...
Goat polyclonal to SART1 ( Abpromise for all tested applications). Antigen: Synthetic peptide: GSSKKHRGEKEAA, corresponding to N terminal amino acids 2-14 of Human SART1. Entrez Gene ID: 909...
IkappaB-alpha (112B2) Mouse mAb...
...
Biology Products: